{"id":51383,"date":"2022-11-30T13:02:03","date_gmt":"2022-11-30T12:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/astrazeneca-showcases-strength-of-hematology-portfolio-and-pipeline-across-multiple-hard-to-treat-conditions-at-ash-2022\/"},"modified":"2022-11-30T13:02:03","modified_gmt":"2022-11-30T12:02:03","slug":"astrazeneca-showcases-strength-of-hematology-portfolio-and-pipeline-across-multiple-hard-to-treat-conditions-at-ash-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/astrazeneca-showcases-strength-of-hematology-portfolio-and-pipeline-across-multiple-hard-to-treat-conditions-at-ash-2022\/","title":{"rendered":"AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022"},"content":{"rendered":"
\n

\nCALQUENCE real-world evidence and long-term follow-up data, as well as research collaborations, will reinforce efficacy and safety across B-cell malignancies<\/i><\/b>\n<\/p>\n

\nEarly clinical data will illustrate potential of multiple pipeline molecules, including TNB-486 (AZD0486), across hematologic malignancies<\/i><\/b>\n<\/p>\n

\nResearch from Alexion, AstraZeneca Rare Disease, offers new insights to <\/i><\/b>accelerate innovation and improve time to diagnosis for several rare diseases<\/i><\/b>\n<\/p>\n

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca will present 47 abstracts showcasing new data from across its hematology portfolio and clinical pipeline, demonstrating its commitment to redefining care for hard-to-treat blood diseases at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, December 10 to 13, 2022.\n<\/p>\n

<\/a><\/p>\n

\nA total of eight approved and potential new medicines will be featured across more than 10 types of blood cancers and rare diseases, including data in chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and amyloid light chain (AL) amyloidosis.\n<\/p>\n

\nAnas Younes, Senior Vice President, Oncology R&D, AstraZeneca, said: \u201cAt this year\u2019s ASH Annual Meeting, our data demonstrate the broad potential of our hematology pipeline and the continued strength of our approved medicines. Data are being highlighted from many of our early-stage molecules, including clinical trials of TNB-486 (AZD0486), a B-cell targeting T-cell engager, and presentations of long-term follow-up data will show the consistent safety and efficacy profile of CALQUENCE.\u201d\n<\/p>\n

\nGianluca Pirozzi, Senior Vice President, Head of Development and Safety, Alexion, AstraZeneca Rare Disease said: \u201cThe depth and breadth of Alexion data at this year\u2019s ASH Annual Meeting reinforce the importance of earlier diagnosis and disease management for rare diseases that are often not well-understood. We will share research across several therapy areas \u2013 including an oral presentation demonstrating the potential of vemircopan, an investigational, second-generation factor D inhibitor as monotherapy treatment of paroxysmal nocturnal hemoglobinuria \u2013 underscoring our leadership and unwavering commitment to driving critical innovations in rare disease.\u201d\n<\/p>\n

\nCALQUENCE\u00ae<\/sup><\/b> <\/i>(acalabrutinib) real-world evidence and long-term follow-up data support consistent efficacy and safety profile<\/b>\n<\/p>\n